Photocure ASA, known for its innovations in bladder cancer diagnostics, has partnered with Artera, a leader in precision medicine, to advance the evaluation of digital pathology tests for bladder cancer. This collaboration will leverage data from Photocure's blue light cystoscopy (BLC®) registry alongside Artera's AI-powered Bladder Test, which is currently under development. The initiative aims to enhance precision diagnostics in uro-oncology, a field where the need for personalized treatment options is growing. Bladder cancer, which ranks as the 8th most common cancer worldwide, presents significant challenges due to its high recurrence rates and treatment costs. The partnership seeks to develop and validate multimodal AI histopathology biomarkers to assist urologists in making more informed treatment decisions for patients with non-muscle invasive bladder cancer (NMIBC). By integrating real-world evidence from the BLC registry, the collaboration aims to optimize the accuracy of diagnoses and improve patient outcomes. Both companies express excitement about the potential to set new standards in bladder cancer management and enhance personalized care.